Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	45.82	7.27	8.19	20.3	16.74
Short-Term Investments	14.4	-	4.93	-	-
Cash & Short-Term Investments	60.21	7.27	13.12	20.3	16.74
Cash Growth	728.67%	-44.62%	-35.38%	21.31%	26.66%
Other Current Assets	0.08	0.07	0.05	0.22	0.06
Total Current Assets	60.29	7.33	13.17	20.52	16.8
Property, Plant & Equipment	-	0.01	0.06	-	-
Other Long-Term Assets	-	-	-	-	0.07
Total Assets	60.29	7.35	13.23	20.52	16.87
Accounts Payable	2.25	1.76	3.13	1.58	1.18
Accrued Expenses	3	-	-	-	-
Total Current Liabilities	5.25	1.76	3.13	1.58	1.18
Long-Term Leases	-	-	0.01	-	-
Total Liabilities	5.25	1.76	3.14	1.58	1.18
Common Stock	0.01	0	0.01	0.01	0.01
Additional Paid-In Capital	130.79	65.81	61.87	60.22	47.87
Retained Earnings	-75.79	-60.21	-51.8	-41.29	-32.19
Comprehensive Income & Other	0.04	-0.01	0.01	-0	-0.01
Total Common Equity	55.04	5.59	10.09	18.94	15.69
Shareholders' Equity	55.04	5.59	10.09	18.94	15.69
Total Liabilities & Equity	60.29	7.35	13.23	20.52	16.87
Total Debt	-	-	0.01	-	-
Net Cash (Debt)	60.21	7.27	13.11	20.3	16.74
Net Cash Growth	728.67%	-44.58%	-35.42%	21.31%	26.66%
Net Cash Per Share	15.89	2.63	5.15	8.14	7.64
Filing Date Shares Outstanding	6.11	3.49	2.64	2.52	2.51
Total Common Shares Outstanding	6.1	2.98	2.59	2.52	2.29
Working Capital	55.04	5.58	10.04	18.94	15.62
Book Value Per Share	9.02	1.87	3.90	7.52	6.85
Tangible Book Value	55.04	5.59	10.09	18.94	15.69
Tangible Book Value Per Share	9.02	1.87	3.90	7.52	6.85

Updated Nov 8, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q